For example, intraventricular administration of IFN-α was used to treat central nervous system (CNS) diseases induced by viral infection such as subacute sclerosing panencephalitis (SSPE) (Yalaz et al., 1992; Kwak et al., 2019). Here, IFNA1 is linked to subacute sclerosing panencephalitis.